NeoGenomics Ebitda Over Time
| NEO Stock | USD 17.90 0.27 1.49% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out NeoGenomics Performance and NeoGenomics Correlation. NeoGenomics |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.61) | Revenue Per Share 5.098 | Quarterly Revenue Growth 0.104 | Return On Assets (0.03) |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare NeoGenomics and related stocks such as Molecular Partners, MediciNova, and Anebulo Pharmaceuticals Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MOLN | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 3 M | (1 M) | (18.1 M) | (24.1 M) | (36.3 M) | (32.7 M) | (59.6 M) | (60.9 M) | 120.8 M | (59.5 M) | (56.6 M) |
| MNOV | (2 M) | (16.1 M) | (11 M) | (3.9 M) | (9.2 M) | (8.8 M) | (10.8 M) | (12.9 M) | (15.6 M) | (14 M) | (14.2 M) | (10.2 M) | (13.9 M) | (9.9 M) | (10.4 M) |
| ANEB | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (30.2 M) | 5.6 K | (11.8 M) | (8.1 M) | (8.5 M) |
| STTK | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (23.4 M) | (36.3 M) | (43.9 M) | (100.3 M) | (87.6 M) | (83.2 M) |
| IPSC | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (51.4 M) | (89.9 M) | (119.3 M) | (121.2 M) | (127.3 M) |
| AVTE | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (8.9 M) | (23 M) | (53.2 M) | (81.3 M) | (77.2 M) |
| ADAG | (14.8 M) | (14.8 M) | (14.8 M) | (14.8 M) | (14.8 M) | (14.8 M) | (14.8 M) | (14.8 M) | (14.8 M) | (16.7 M) | (41.3 M) | (70 M) | (77.4 M) | (15 M) | (15.7 M) |
| ACRV | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (15.4 M) | (32.3 M) | (59.9 M) | (56.9 M) |
| RZLT | (45.5 K) | (45.5 K) | (6 M) | (5.2 M) | (10.6 M) | (14.2 M) | (19.2 M) | (25.2 M) | (25.5 M) | (20.3 M) | (22.9 M) | (41.8 M) | (51.4 M) | (68.4 M) | (65 M) |
NeoGenomics and related stocks such as Molecular Partners, MediciNova, and Anebulo Pharmaceuticals Ebitda description
My Equities
My Current Equities and Potential Positions
| NeoGenomics | NEO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Florida; U.S.A |
| Exchange | NASDAQ Exchange |
USD 17.9
Check out NeoGenomics Performance and NeoGenomics Correlation. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
NeoGenomics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.